MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 265 filers reported holding MYRIAD GENETICS INC in Q4 2018. The put-call ratio across all filers is 2.28 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $875,000 | -36.8% | 30,097 | 0.0% | 0.99% | -26.3% |
| Q3 2018 | $1,384,000 | +23.0% | 30,097 | 0.0% | 1.35% | +23.6% |
| Q2 2018 | $1,125,000 | +26.5% | 30,097 | 0.0% | 1.09% | +23.8% |
| Q1 2018 | $889,000 | -82.0% | 30,097 | -79.1% | 0.88% | -81.9% |
| Q4 2017 | $4,949,000 | -0.2% | 144,097 | +5.1% | 4.88% | -13.9% |
| Q3 2017 | $4,961,000 | +22.2% | 137,111 | -12.7% | 5.67% | +21.3% |
| Q2 2017 | $4,060,000 | +34.6% | 157,111 | 0.0% | 4.67% | +41.2% |
| Q1 2017 | $3,017,000 | +33.1% | 157,111 | +15.6% | 3.31% | +31.5% |
| Q4 2016 | $2,266,000 | +15.3% | 135,911 | +42.3% | 2.52% | +19.0% |
| Q3 2016 | $1,966,000 | -25.7% | 95,511 | +22.7% | 2.11% | -16.9% |
| Q2 2015 | $2,645,000 | -4.0% | 77,810 | 0.0% | 2.54% | +3.3% |
| Q1 2015 | $2,754,000 | +3.9% | 77,810 | 0.0% | 2.46% | -5.4% |
| Q4 2014 | $2,650,000 | – | 77,810 | – | 2.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
| Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
| Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
| PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
| EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
| Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
| AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
| Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
| Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |